Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Pfizer logo
PfizerPFE
1.8×+0.2×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Amgen logo
AmgenAMGN
20.6×-6.3×
Royalty Pharma logo
Royalty PharmaRPRX
2.1×+0.7×

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$33.54B+193%
Enterprise value$33.26B+198%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Calculated from Revolution Medicines, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revolution Medicines, Inc.'s price / book?
Revolution Medicines, Inc. (RVMD) reported price / book of 12.8× in Q1 2026.
How has Revolution Medicines, Inc.'s price / book changed year-over-year?
Revolution Medicines, Inc.'s price / book increased by 306.2% year-over-year, from 3.2× to 12.8×.
What is the long-term trend for Revolution Medicines, Inc.'s price / book?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s price / book has grown at a 11.4% compound annual growth rate (CAGR), from 14.3× to 22.1×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.